Vibramycin is a broad-spectrum antibiotic synthetically derived from oxytetracycline, and is available as Vibramycin Monohydrate (doxycycline monohydrate); Vibramycin Hyclate and Vibra-Tabs (doxycycline hydrochloride hemiethanolate hemihydrate); and Vibramycin Calcium (doxycycline calcium) for oral administration.
To reduce the development of drug-resistant bacteria and maintain effectiveness of Vibramycin and other antibacterial drugs, Vibramycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Doxycycline is indicated for the treatment of the following infections:
- Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.
- Respiratory tract infections caused by Mycoplasma pneumoniae.
- Lymphogranuloma venereum caused by Chlamydia trachomatis.
- Psittacosis (ornithosis) caused by Chlamydia psittaci.
- Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.
- Inclusion conjunctivitis caused by Chlamydia trachomatis.
- Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis.
- Nongonococcal urethritis caused by Ureaplasma urealyticum.
- Relapsing fever due to Borrelia recurrentis.
Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:
- Chancroid caused by Haemophilus ducreyi
- Plague due to Yersinia pestis (formerly Pasteurella pestis).
- Tularemia due to Francisella tularensis (formerly Pasteurella tularensis).
- Cholera caused by Vibrio cholerae (formerly Vibrio comma).
- Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus).
- Brucellosis due to Brucella species (in conjunction with streptomycin).
- Bartonellosis due to Bartonella bacilliformis.
- Granuloma inguinale caused by Calymmatobacterium granulomatis.
Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.
Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:
- Escherichia coli.
- Enterobacter aerogenes (formerly Aerobacter aerogenes).
- Shigella species.
- Acinetobacter species (formerly Mima species and Herellea species).
- Respiratory tract infections caused by Haemophilus influenzae.
- Respiratory tract and urinary tract infections caused by Klebsiella species.
Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
- Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae).
Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:
- Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.
- Syphilis caused by Treponema pallidum.
- Yaws caused by Treponema pertenue.
- Listeriosis due to Listeria monocytogenes.
- Vincent's infection caused by Fusobacterium fusiforme.
- Actinomycosis caused by Actinomyces israelii.
- Infections caused by Clostridium species.
In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.
In severe acne, doxycycline may be useful adjunctive therapy.
Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.
Published Studies Related to Vibramycin (Doxycycline)
Effect of doxycycline vs placebo on retinal function and diabetic retinopathy
progression in mild to moderate nonproliferative diabetic retinopathy: a
randomized proof-of-concept clinical trial. 
IMPORTANCE: Microglia have been associated with inflammatory changes underlying
diabetic retinopathy. OBJECTIVE: To investigate whether low-dose oral doxycycline monohydrate, a drug
capable of inhibiting microglial activation, can improve or slow the
deterioration of retinal function and whether it can induce regression or slow
progression of diabetic retinopathy in patients with mild to moderate
nonproliferative diabetic retinopathy (NPDR)...
The effect of prolonged systemic doxycycline therapy on serum tissue degrading
proteinases in coronary bypass patients: a randomized, double-masked,
placebo-controlled clinical trial. 
biomarkers during 4 months of doxycycline therapy in coronary bypass patients... CONCLUSIONS: Doxycycline decreases the systemic inflammatory burden in patients
Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux
capacity from macrophages. 
removal from macrophages... CONCLUSIONS: Our results suggest that SDD treatment may reduce the risk of
Safety and efficacy of WC2031 versus vibramycin for the treatment of
uncomplicated urogenital Chlamydia trachomatis infection: a randomized,
double-blind, double-dummy, active-controlled, multicenter trial. 
difficulties with the recommended twice-daily doxycycline regimen... CONCLUSIONS: WC2031 was noninferior to Vibramycin for uncomplicated urogenital
A study of the clinical activity of a gel combining monocaprin and doxycycline: a
novel treatment for herpes labialis. 
doxycycline in vivo against herpes labialis... CONCLUSION: Combining monocaprin with low-dose doxycycline offers an effective
Clinical Trials Related to Vibramycin (Doxycycline)
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole) [Completed]
This study will look at the safety, effectiveness, and tolerability of combination
medications for the initial treatment of non-gonococcal urethritis (NGU). NGU is
inflammation of the tube that carries urine from the bladder. NGU is caused by bacteria that
may be passed from person to person during sex. This study will compare the 2 currently
recommended NGU treatments, doxycycline and azithromycin, taken with tinidazole (another
medication to treat certain sexually transmitted infections). Tinidazole used with
doxycycline or azithromycin may cure NGU better than when doxycycline or azithromycin is
used alone. Study participants will be 300 men ages 16-45 years with NGU attending sexually
transmitted disease clinics in Birmingham, AL; New Orleans, LA; Durham, NC; and Baltimore,
MD. Study participation will last 7 weeks and involve 3 visits. At each visit, participants
will provide a urine sample, have 2 urethral swabs, and have their urethra checked for
discharge indicating infection.
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans [Completed]
Obesity is a heightened state of inflammation in which production of cytokines and matrix
metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin
resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will
enhance insulin sensitivity and decreases inflammation in obese participants with type 2
Doxycycline Effects on Inflammation in Cystic Fibrosis [Completed]
Doxycycline is known to exhibit immune modulatory activities beyond its antibacterial
effects. In particular, doxycycline is a potent inhibitor of matrix metalloproteinase 9,
which is a protease derived largely from neutrophils. Recent studies demonstrate a
significant correlation between pulmonary disease severity and sputum concentrations of
MMP-9 in patients with CF. In addition, sputum MMP-9 levels are associated with airway
remodeling in CF.
The goal of this study is to determine the therapeutic potential of doxycycline in
modulating host airway inflammation in patients with CF. Specifically, the study will
characterize the PK /PD of doxycycline, evaluate the safety of short term therapy, and
explore the concentration effect relationship between doxycycline exposure and sputum
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease [Not yet recruiting]
Kawasaki disease (KD) affects infants and young children causing inflammation of the skin
and blood vessels including the coronary arteries of the heart. Despite the currently
available therapy, about one third of children develop enlargement of the coronary arteries
that can lead to serious complications such as coronary artery stenosis, heart attack and
Kawasaki disease is the most common heart disease in children in the USA and it is
especially common among the children of Hawaii. Every year, 50-90 children are diagnosed
with KD in Hawaii and unfortunately there is no medication available to successfully prevent
coronary artery damage in a subset of cases.
During the first few weeks of the illness, cells of the immune system attack the coronary
arteries and release a special substance (MMP) that is responsible for the coronary artery
enlargement. There is a common antibiotic, doxycycline that can specifically block the
action of this special substance (MMP). Research done on animals with KD showed that
doxycycline was able to block this special substance and prevent enlargement of coronary
arteries. Research in adults with enlargement of the main artery in their abdomen also
showed that doxycycline may improve the outcome. Based on these studies doxycycline may be a
promising therapy for children with KD, who develop enlargement of the coronary arteries.
The investigators' proposed research study will assess the usefulness of doxycycline in
preventing the progressive enlargement of coronary arteries in children with KD. The
investigators plan to perform a small (pilot) study to evaluate how good is doxycycline in
preventing coronary artery enlargement. The investigators will treat 25 children with KD and
enlarged coronary arteries for two weeks with doxycycline and assess the change in coronary
arteries as well as the blood levels of the special substance (MMP). If doxycycline proves
to be beneficial in this small study, the investigators are going to design a large research
study involving multiple institutions on Hawaii and the mainland and will recruit more
children to be certain about the value of the proposed treatment. The investigators'
proposal may change the treatment protocol of KD and could present a possible treatment for
children with enlarged coronary arteries preventing potentially devastating consequences.
Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis [Completed]
The aim of this randomised, double-blind crossover study was to determine whether
Doxycycline has an impact on the persistent symptoms post-neuroborreliosis, through
alterations in the immune response and whether such an effect could influence the clinical
Reports of Suspected Vibramycin (Doxycycline) Side Effects
Drug Hypersensitivity (8),
Blood Cholesterol Abnormal (6),
Blood Pressure Fluctuation (6),
Abdominal Discomfort (3),
Lyme Disease (3),
Ulcer (3), more >>
Page last updated: 2015-08-10